What is the role of insulin-like growth factor 2 (IGF2)-derived miR-483-3p in macrosomia?
Introduction
Macrosomia is a pregnancy-associated disease defined as birth weight ≥4000 g. It was recognized as a cause of numerous maternal and perinatal adverse outcomes including prolonged labor, increased chance of cesarean delivery, post-partum infection, fetal trauma, and perinatal mortality , Ng et al., 2010 . Furthermore, children born with macrosomia are prone to develop adult obesity, chronic disease and some cancers (Ng et al., 2010 , Lau et al., 2011 , Yu et al., 2011 . It has been identified that diabetes mellitus is a risk factor for the delivery of macrosomia (Kc et al., 2015 , Valvi et al., 2017 . However, not all the macrosomia infants are born to diabetic mothers, and many cases of macrosomia remain unexplained.
The placenta, as the interface between fetus and mother, plays a critical role in supporting fetal growth and development Powell, 2007, 2013) . It provides an immunological barrier between fetus and mother, and mediates the transfer of nutrients and wastes. Recent evidence suggests that placental weight of the macrosomia was significantly higher than those of the normal birth weight. The development of macrosomia is reportedly attributable to excessive proliferation of the placenta cells (Salafia et al., 2008 , Unek et al., 2014 . However, the molecular mechanisms responsible for the development of macrosomia remain largely unknown.
MicroRNAs (miRNAs) are small non-coding RNAs that function as regulators of gene expression by antisense complimentarily to 3′-untranslated regions (3′-UTR) of target mRNAs, participating in placental differentiation and the maintenance of pregnancy (Mayor-Lynn et al., 2011) . Previous studies have shown that the aberrant expression of miRNAs, such as miR-17-92, miR-21 and miR-16 in placenta, are associated with macrosomia (Jiang et al., 2014 , Li et al., 2015 . miR-483-3p was identified as an intron-derived miRNA located in the second intron of the insulin-like growth factor 2 (IGF2) gene, an important polypeptide regulator of growth. IGF2 has been recognized to have an important role in mediating fetal and postnatal growth. Previous studies have reported that IGF2 mRNA levels were significantly higher in placental tissues of macrosomia than those in controls (Fowden, 2003; Jiang et al., 2009) . Evidence suggests that intronic miRNAs may be co-expressed with their host genes and play a similar role. However, the function of IGF2-derived miR-483-3p in macrosomia remains unknown. Here, we demonstrate that RB1 inducible coiled-coil 1 (RB1CC1) has a key role in the mediation of the proliferative effects of miR-483-3p in the development of macrosomia. Our findings highlight the functional and the potential implication of IGF2-derived miR-483-3p for macrosomia intervention and therapy.
Materials and Methods

Clinical specimens and cell culture
Placental tissues from 30 macrosomia and 30 normal neonates were obtained from Changzhou Maternity and Child Health Hospital. Macrosomia was defined as neonate whose birth weight was ≥4000 g. Mothers of both groups had no diabetes or other complications during pregnancy. After removal of the fetal membranes, three pieces of placental tissue of 1 × 1 × 1 cm 3 size were randomly taken from the center of the maternal side within 5 min after the delivery of the placenta. Then the tissues were washed using sterile saline and frozen in liquid nitrogen, and stored at −70°C. HTR-8/SVneo cells were maintained in RPMI1640 containing 10% fetal calf serum (FCS) (Gibco, ThermoFisher, Waltham, MA, USA), 1% penicillin and 1% streptomycin. The cells were grown at 37°C in a humidified incubator containing 5% CO 2 .
Ethical approval
This study was approved by Nanjing Medical University Ethics Committee. Written informed consent was obtained from all the pregnant women prior to participation.
RNA extraction and qRT-PCR
Total RNA containing miRNAs was isolated from placenta tissues and cultured cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. Reverse transcription was performed by Takara RNA PCR kit (TaKaRa, Dalian, Japan), and real-time PCR was conducted using the SYBR green detection system (TaKaRa, Dalian, Japan) using ABI Prism 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The U6 small nuclear RNA and GAPDH mRNA were used as internal controls for miRNA and mRNA quantification, respectively. All the reactions were run in triplicate. Primers for transfection and PCR (Invitrogen, Carlsbad, CA, USA) are shown in Supplementary Table S1 .
Transfection of miRNA mimics, inhibitors and siRNAs
The IGF2 sequence was synthesized and cloned into pcDNA 3.1 vector (GenScript, Nanjing, China). siRNA duplex against human RB1CC1, microRNA mimics, inhibitors and negative controls were designed and purchased from GenePharma (GenePharma, Shanghai, China). Transient transfection was performed using Lipofectamine 2000 reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). IGF2 transcript sequence is shown in Supplementary Table S2 .
Protein extraction and western blot analysis
Total proteins were extracted and quantified at 48 h after transfection. Equal amounts of total protein were separated by 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and subsequently transferred to nitrocellulose membranes (Merck Millipore, Billerica, MA, USA). After blocking with 5% defatted milk in Tris buffered saline with Tween 20 (TBST) for 1 h at room temperature, the membranes were incubated with antibody for RB1CC1 and GAPDH (Abcam, Cambridge, UK) overnight at 4°C. After TBST washing, they were incubated with secondary antibody for 1 h at room temperature. Proteins were detected using an enhanced chemiluminescence system (Merck Millipore, Billerica, MA, USA), and images were captured using Quantity One software (Bio-Rad, Hercules, CA, USA).
Cell proliferation assay
Cells were seeded in 96-well plates at a density of 1 × 10 3 cells/well. After transfection for 24 h, cell proliferation was assayed using Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). The absorbance at 450 nm was recorded with TECAN infinite M200 Multimode microplate reader (Tecan, Mechelen, Belgium) using culture medium as a blank. The experiments were repeated thrice independently.
Cell cycle and apoptosis assay
For apoptosis assays, FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, USA) was used after transfection. Cells were co-stained with Annexin V-FITC and propidium iodide (PI) for 15 min at room temperature in the dark and analyzed immediately by flow cytometry. For cell cycle analysis, cells were fixed in 75% alcohol and stained with PI (BD Biosciences, San Diego, CA, USA) at 37°C for 30 min before flow cytometry analysis. Cells were analyzed by flow cytometry (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). The cell cycle distribution was analyzed by Modfit LT version 3.0 software (Verity Software House, Toshan, ME, USA).
Dual luciferase reporter assay
The putative targets of miR-483-3p were predicted using the TargetScan (http://www.targetscan.org/), miRanda (www.microrna.org/), miRDB (http://mirdb.org/) and DIANA algorithms (http://diana.imis.athenainnovation.gr/DianaTools/). The RB1CC1 3′-UTR containing the predicted miR-483-3p-binding sites were cloned into the pGL3-REPORT vector (Genscript, Nanjing, China). A mutant luciferase vector with miR-483-3p one pairing site deleted was also constructed. The reporter plasmid was co-transfected with miR-483-3p mimics or a negative control mimics into HEK 293 T cells using Lipofectamine 2000. Forty-eight hours after transfection, luciferase activity was determined with the DualLuciferase Reporter Assay System (Promega, WI, USA) according to manufacturer instructions. The sequence of RB1CC1 3′-UTR and RB1CC1 3′-UTR-mut is shown in Supplementary Table S3 .
Statistical analysis
The results are presented as the mean ± SEM, and the experiments were repeated three times. Data were analyzed by unpaired two-side Student's t-test or Mann-Whitney U test. P < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS software for Windows 19.0 (SPSS Inc., Chicago, IL, USA), and figures were presented by GraphPad Prism version 5.01 (GraphPad Software Inc., San Diego, CA, USA).
Results miR-483-3p and its host gene IGF2 are concomitantly up-regulated in macrosomia
To determine the potential role of IGF2-derived miR-483-3p in the development and progression of macrosomia, we evaluated the expression levels of miR-483-3p and its host gene IGF2 in 60 placenta samples. Maternal and infant characteristics of the study are presented in Table I . The birth weight of the macrosomia group and weight gain during pregnancy was significantly higher than those of controls (P < 0.001). However, no significant differences were found between macrosomia subjects and controls in maternal age (P = 0.572), gestational age (P = 0.160), maternal BMI before pregnancy (P = 0.750) and fetal gender (P = 1.000).
As shown in Fig. 1 , miR-483-3p (median = 0.044 and 0.022 for NDFMS and control, respectively) and IGF2 (median = 0.017 and 0.007 for NDFMS and control, respectively) were significantly overexpressed in placenta tissues of macrosomia compared with controls (P = 0.004 and 0.016 for miR-483-3p and IGF2, respectively) (Fig. 1A, B) . As expected, statistical analysis showed a significant positive correlation of expression between miR-483-3p and IGF2 (Fig. 1C , r = 0.375, P = 0.003).
As an intronic miRNA, miR-483-3p is thought to be transcribed together with its corresponding host gene. After transfection of IGF2 expression plasmid in HTR-8/SVneo cell line, we found that the expression levels of IGF2 and miR-483-3p were significantly upregulated (P = 0.022 and 0.027) ( Fig. 2A, B) . However, miR-483-3p did not affect the expression of its host gene IGF2 (Fig. 2C) . Thus, these data suggest that miR-483-3p and its host gene IGF2 might have functional relevance in the development of macrosomia, and intronic miR-483-3p induces its effects without regulating the host gene IGF2.
miR-483-3p promotes cell proliferation in vitro
To investigate the role of miR-483-3p dysregulation in macrosomia, we transfected miR-483-3p mimic or inhibitor to HTR-8/SVneo cells. Cell proliferation, cell cycle and apoptosis assays were conducted. The CCK-8 assay showed that the cell proliferation was enhanced significantly in HTR-8/SVneo cells transfected with miR-483-3p mimic compared with the cells transfected with negative control. By contrast, miR-483-3p knockdown markedly reduced the proliferation of cell proliferation (Fig. 3A) . Then we investigated the mechanism underlying the growth promotion by miR-483-3p in HTR-8/SVneo cells by observing the changes in the cell cycle phase distribution. The result demonstrated that miR-483-3p inhibition significantly caused upregulation in G1 stage (P = 0.002) and down-regulation in S stage (P < 0.001) (Fig. 3B) . However, neither overexpression nor inhibition of miR-483-3p affected apoptosis when compared with the control (Fig. 3C ). These observations suggest that miR-483-3p might contribute to the aberrant cell proliferation in macrosomia placentas.
miR-483-3p targeted the 3′UTR of RB1CC1 directly
To further explore the mechanism by which miR-483-3p executes its function in macrosomia, target prediction bioinformatic algorithms (TargetScan, PicTar, DIANA LAB, and miRwalk) were used to identify the potential downstream target genes (Table II) . Since miRNAs function by suppressing the expression of their target genes, mRNA expression levels of RB1CC1, RBAK, TACC2, FHL1, PTGS1 were examined in HTR-8/SVneo cells and placentas (Supplementary Information  Fig. S1 ). The results showed that the mRNA and protein level of RB1CC1 were both suppressed in miR-483-3p mimic-transfected cells, whereas opposite trends were found in the cells transfected with miR-483-3p inhibitor (Fig. 4A, B) . Additionally, the RNA (median = 0.079 and 0.056 for NDFMS and control, respectively) and protein (mean = 1.420 and 0.95 for NDFMS and control, respectively) level of RB1CC1 was appreciably lower in placentas of neonates with macrosomia compared with those of controls (P = 0.018 and 0.044) (Fig. 4C, D) . To confirm whether miR-483-3p directly targets the 3′UTR of RB1CC1, we constructed luciferase reporter plasmids containing wildtype or mutated RB1CC1 3′-UTR sequences downstream of the renilla reporter gene (Fig. 5A) . Luciferase assay showed that miR-483-3p significantly decreased luciferase activity of wild-type RB1CC1 3′UTR reporter, while had no significant effect on the luciferase activity of the mutant-type one, suggesting that miR-483-3p down-regulates RB1CC1 expression by directly targeting its 3′UTR (Fig. 5B) . Taken together, these results demonstrated that RB1CC1 is directly regulated by miR-483-3p at the post-transcriptional level.
RB1CC1 is involved in the regulation of cell proliferation by miR-483-3p
To confirm whether miR-483-3p functions in cell proliferation via targeting to RB1CC1, we silenced the expression of RB1CC1 in HTR-8/ SVneo cells with specific siRNAs. The results showed that RB1CC1 silencing significantly increased the proliferation of HTR-8/SVneo cells (P = 0.029), which was similar to the effect induced by miR-483-3p. Moreover, inhibition of proliferation and cell cycle mediated by miR-483-3p inhibitor can be partially abrogated when HTR-8/SVneo cells were transfected together with si-RB1CC1, showing no statistically significant differences compared with control group (Fig. 6A, B) . These data implicated that RB1CC1 is an important mediator of cell growth regulation for miR-483-3p in HTR-8/SVneo cells. Figure 4 miR-483-3p regulates RB1CC1 expression at mRNA and protein levels. (A) mRNA and (B) protein level of RB1CC1 were determined in miR-483-3p mimic or inhibitor-transfected cells. (C) mRNA and (D) protein level of RB1CC1 were examined in placentas. NC stands for mimic negative control, and NC-In stands for inhibitor negative control. The boxes represent the interquartile range (25-75th percentile), line in the boxes represents the median (50th percentile), plus in the boxes represents mean, and the whisker bars extend to 1.5 times the interquartile range. Results are expressed as the mean ± SEM (n = 3). Data were analyzed with Student's t-test or Mann-Whitney U test (significant differences: * P < 0.05; ** P < 0.01).
NDFMS, non-diabetic fetal macrosomia.
To demonstrate the clinical relevance of these findings, we analyzed the correlation between RB1CC1 and miR-483-3p expression. As shown in Figure 6C , RB1CC1 mRNA was negatively correlated with miR-483-3p in placentas. These results indicated that RB1CC1 downregulation might be associated with the increased expression level of miR-483-3p in macrosomia (r = −0.539, P < 0.001). Together with in vitro results, these data indicated that miR-483-3p is a miRNA which participates in the development of macrosomia through targeting RB1CC1. In addition, these data indicated that miR-483-3p may be a promising biomarker and target in a clinical therapy for macrosomia.
Discussion
Recent studies have indicated that~37% of the known mammalian miRNAs are located in the introns of protein coding genes (GriffithsJones et al., 2006) , and most of the miRNAs expression directly depend on the transcription of their host genes. These intronic miRNAs may be involved in physiological or pathological processes, and act in synergy with or antagonistically against the functions of their host genes (Lutter et al., 2010) . Research has shown that miR-483-5p is positively correlated with its host gene Igf2 and can function as a partner for Igf2 . In our study, IGF2 and its intronic miR-483-3p were both increased in macrosomia placentas, and the correlation between them was statistically significant but not strong. We speculate that transcription factors, signaling pathways or DNA methylation, may also regulate the production of miR-483-3p. Larger sample size of placenta tissues should also be included in future studies. The expression levels of IGF2 and miR-483-3p were up-regulated after IGF2 was overexpressed, indicating that miR-483-3p was co-expressed with its host gene IGF2. However, miR-483-3p did not feedbackregulate IGF2 in cells with overexpressed level of miR-483-3p. Thus, we suspect that miR-483-3p may function separately in macrosomia as its host gene IGF2.
Studies have reported that mature miR-483-3p is overexpressed in many human cancers including malignant mesothelioma, Wilms' tumors and pancreatic cancer (Guled et al., 2009 , Veronese et al., 2010 , Hao et al., 2011 , Abue et al., 2015 . miR-483-3p was considered to be an oncogenic microRNA and was shown to promote tumor cell proliferation and support cell survival by protecting cells from apoptosis (Veronese et al., 2010) . Additionally, it is known that many similarities exist between trophoblast cells of the human placenta and malignant tumors, such as rapid proliferation, invade maternal blood vessels and acquisition of a rich blood supply (Novakovic et al., 2008) . However, the functional significance of miR-483-3p in the development of macrosomia has not been explored thus far. In this study, we identified that up-regulation of miR-483-3p could significantly enhance the HTR-8/SVneo cell proliferation, while inhibition of miR-483-3p markedly reduced cell proliferation. Thus, overexpressed miR-483-3p might favor cell survival by aberrant cell proliferation, resulting in the overgrowth of placentas in macrosomia.
In the present study, we found that RB1CC1 was a direct target of miR-483-3p. siRNAs, targeting RB1CC1 mimicked the effects of miR-483-3p. In macrosomia placentas, the expression levels of RB1CC1 were significantly lower at both mRNA and protein levels than normal control placentas. RB1CC1 has been recognized as an important tumor suppressor, and involved in the tumorigenesis of human breast cancer (Ikebuchi et al., 2009) . It was suggested that RB1CC1 was involved in the signaling of proliferation, cell cycle, apoptosis and autophagy progression through interacting with different proteins (Hara et al., 2008 , Li et al., 2016 .
Previous studies showed that RB1CC1 was an important RB1 pathway regulator, which could globally activate the transcription of RB1, p16 and p21, and suppress cell cycle progression or tumor growth by forming a complex with hSNF5 and/or p53 (Chano et al., 2010) . Among the regulators of the RB1 pathway, RB1 was identified as a tumor suppressor gene which played a key role in cell cycle regulation (Rajaraman et al., 2010) . Loss of Rb leads to excessive proliferation of trophoblast cells and widespread developmental defects in mice (Wu et al., 2003) . In our previous study, RB1 was found to be inhibited in mRNA and protein levels in macrosomia placentas compared with control (Li et al., 2015) . Taken together, our research indicates that miR-483-3p targeting RB1CC1 plays an essential role in macrosomia by the RB1 pathway.
In summary, we found that miR-483-3p and its host gene IGF2 were up-regulated in macrosomia, and their up-regulation synergistically facilitated the proliferation of HTR-8/SVneo cells. Moreover, miR-483-3p exerted its function, at least partially, through directly targeting RB1CC1. Our results indicated new insights into the functional associations between intronic miRNA and its host gene in the development of macrosomia. Importantly, the findings provide that IGF2-derived intronic miR-483-3p shows great therapeutic potential for macrosomia.
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